This category can also help with the "nothing sounds good" problem that shows up on GLP-1s
These signs are: Sales of Eli Lillys dual agonist GLP-1 diabetes drug, Mounjaro (tirzepatide), approved in May 2022, exceeded $5 billion in 2023, its first full year on the market
However, the exact interplay between 5-HT2A-dependent and TrkB-direct mechanisms remains an area of intense investigation and is crucial for understanding how to pharmacologically separate therapeutic plasticity from hallucinogenic effects
They include being on the starter dose of 2.5 mg, needing a higher dose, other underlying medical reasons or hormonal imbalances, not eating in a calorie deficit, not getting enough protein and dietary fiber, or not working out
My name's Trina Wilcox, your host for this episode